Published in Cancer Weekly, March 2nd, 1998
The two studies were similar in design, with one conducted by the AIDS Malignancy Consortium (AMC) sponsored by the National Cancer Institute (NCI) and the other conducted directly by Ligand. Both were multicenter, open label studies designed to evaluate the safety and efficacy of Panretin Capsules in patients with AIDS-related KS.
"With positive results from these two studies, and a New Drug Application...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.